Continuing medical educationAlopecia areata: An appraisal of new treatment approaches and overview of current therapies
Section snippets
Approach to treatment
Key points Alopecia areata is unpredictable, and therefore no treatment may be appropriate for a subgroup of patients as spontaneous remission rates range from 8% to 68%, depending on disease severity Extent of hair loss and age of the patient are the most important factors to consider when determining management approaches Patients should be educated about hairpieces and camouflage techniques
Few treatment methods have been evaluated by randomized control trials to determine the most efficacious modalities
Intralesional corticosteroids
Key points Intralesional corticosteroids are considered a first-line treatment method for limited disease, and can be used as adjunctive therapy in extensive disease Patients should be monitored for side effects, including skin atrophy, which may warrant dose modification or treatment discontinuation
Intralesional corticosteroids, most commonly triamcinolone acetonide (TAC), are the criterion standard for treating patchy AA of limited extent and for cosmetically sensitive areas, such as the eyebrows. Tan
Topical corticosteroids
Key points Topical corticosteroids may be used alone or in conjunction with other treatments, including intralesional corticosteroids Pediatric patients may prefer treatment with topical corticosteroids compared to injections
Topically applied corticosteroids likely provide some benefit in AA, especially in patients with limited disease, although the results may be inferior to intralesional therapy. Evidence from split scalp studies has confirmed that regrowth results from local and not systemic effects of
Minoxidil
Key point 5% minoxidil foam or solution may be used as adjuvant therapy in alopecia areata
As a monotherapy for AA, minoxidil may be insufficient to promote complete hair regrowth. Nonetheless, many studies have suggested that it does stimulate hair growth in patients with AA, though less commonly in severe forms of the disease. For example, a long-term study of 30 patients evaluated the efficacy of 3% minoxidil twice daily compared to placebo for 12 weeks followed by 52 weeks of minoxidil treatment. At
Oral corticosteroids
Key point Short courses (6 weeks) of oral corticosteroids are often sufficient to stimulate hair regrowth; however, the side effect profile precludes long-term use and the likelihood of relapse is significant
Systemic corticosteroids are widely used in autoimmune diseases and have demonstrated a significant benefit in most clinical variants of AA, with reduced efficacy in ophiasis and alopecia universalis (AU) types.21 In a study of 32 patients who completed at least a 6-week course of prednisone at a
Methotrexate
Key point Methotrexate may be effective for patients who fail standard therapy
Successful treatment of AA with methotrexate has been reported in both adult and pediatric populations. Chartaux and Joly24 described 33 patients with either AT or AU (mean disease duration, 7.7 years) who failed standard therapy and found that methotrexate (15-25 mg) alone or in combination with oral corticosteroids (prednisone 10-20 mg/day) resulted in complete hair regrowth in 63% of those on combined treatment and 57% of
Topical immunotherapy
Key points Diphenylcyclopropenone has a success rate of approximately 60% to 70%, and is an option for the treatment of patients with extensive disease (>50% scalp involvement) Patients who do not respond to diphenylcyclopropenone may be treated with squaric acid dibutylester
Topical immunotherapy, including squaric acid dibutylester (SADBE) and diphenylcyclopropenone (DPCP), causes an allergic contact dermatitis and through an incompletely understood mechanism may cause antigenic competition, changing the
Novel therapeutic method using Janus kinase inhibitors
Key points Oral Janus kinase inhibitors, including tofacitinib, ruxolitinib, and baricitinib, have been shown to be efficacious in alopecia areata The durability of response to these medications is variable, and most patients experience recurrence of hair loss after discontinuation Topical Janus kinase inhibitors may also be effective but have not been fully evaluated
JAK inhibitors have already demonstrated efficacy in multiple inflammatory diseases, such as psoriasis, rheumatoid arthritis, and vitiligo,
Future directions
Key point Existing medications are being evaluated for their utility in AA
Statins may have antiinflammatory properties,57 and recently 40 mg/10 mg daily simvastatin/ezetimibe for 24 weeks was investigated in patients with AA (40-70% scalp involvement). Of the 19 patients who completed the study, 14 were considered responders, suggesting that this treatment method should be explored in future studies.58 Apremilast, an oral phosphodiesterase-4 inhibitor, has been shown to prevent AA development in human
References (60)
- et al.
Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone
J Am Acad Dermatol
(1991) - et al.
Alopecia areata: a long term follow-up study of 191 patients
J Am Acad Dermatol
(2006) - et al.
Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: an intrasubject pilot study
J Am Acad Dermatol
(2015) - et al.
Alopecia areata update
J Am Acad Dermatol
(2000) - et al.
Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis
J Am Acad Dermatol
(2003) Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy
J Am Acad Dermatol
(1987)Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata
J Am Acad Dermatol
(1987)Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata
J Am Acad Dermatol
(1987)- et al.
Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients
J Am Acad Dermatol
(1998) - et al.
Efficacy of topical sensitizers in the treatment of alopecia areata
J Am Acad Dermatol
(1998)
Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis
J Am Acad Dermatol
Alopecia areata update: part II. Treatment
J Am Acad Dermatol
Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation
J Am Acad Dermatol
Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series
J Am Acad Dermatol
Treatment of alopecia areata with squaric acid dibutylester
Clin Dermatol
Squaric acid sensitization is not required for response in the treatment of alopecia areata
J Am Acad Dermatol
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
J Am Acad Dermatol
Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis
J Invest Dermatol
Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients
J Am Acad Dermatol
Tofacitinib for the treatment of alopecia areata and variants in adolescents
J Am Acad Dermatol
Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib
EBioMedicine
Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation
J Allergy Clin Immunol
Treatment of alopecia areata with simvastatin/ezetimibe
J Am Acad Dermatol
The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo
J Dermatol Sci
Camouflage technique for alopecia areata: what is a patient to do?
Dermatol Ther
The pattern and profile of alopecia areata in Singapore–a study of 219 Asians
Int J Dermatol
Treatment of severe alopecia areata with intralesional steroid injections
J Drugs Dermatol
Image gallery: treatment of refractory alopecia universalis with oral tofacitinib citrate and adjunct intralesional triamcinolone injections
Br J Dermatol
Ocular complications of topical, peri-ocular, and systemic corticosteroids
Curr Opin Ophthalmol
Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream
Arch Dermatol
Cited by (177)
SIRT1 downregulation provokes immune-inflammatory responses in hair follicle outer root sheath cells and may contribute to development of alopecia areata
2023, Journal of Dermatological ScienceTreatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
2023, Journal of the American Academy of DermatologyJanus kinase inhibitor as a therapeutic option in alopecia areata. Case report
2023, Revista Colombiana de ReumatologiaFactors influencing alopecia areata treatment decisions: A qualitative assessment
2023, JAAD International
Funding sources: None.
Dr Shapiro is a consultant for Aclaris Therapeutics, Applied Biology, Incyte, Replicel Life Sciences, and Samumed. Dr Christiano is a consultant for Aclaris Therapeutics and a principal investigator for Pfizer. The other authors have no conflicts of interest to declare.
Ms Strazzulla and Dr Wang contributed equally to this article.
Date of release: January 2018
Expiration date: January 2021